Trandolaprilat

Trandolaprilat

SCHEMBL5794079

CC(N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACE P12821 14/20 0.82
MEN1 O00255 2/20 0.82
KMT2A Q03164 2/20 0.82
USP2 O75604 1/20 0.82
LMNA P02545 1/20 0.82
CYP3A4 P08684 1/20 0.79
ALOX15 P16050 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trandolaprilat SCHEMBL156829 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL11076552 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL678354 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL5567196 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL9173132 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL683838 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL9173121 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL11286342 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL9173113 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA
Trandolaprilat SCHEMBL7388097 1.00 ACE (0.82) ACEMEN1KMT2AUSP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2006014916-A3 PREPARATION OF TRANDOLAPRIL REDDYS LAB LTD DR (IN) 2006-08-03 WO disclosed
US-20060079698-A1 Process for the preparation of intermediates of trandolapril and use thereof for the preparation of trandolapril GLENMARK PHARMACEUTICALS LIMITED (IN) 2006-04-13 US disclosed
WO-2006014916-A2 PREPARATION OF TRANDOLAPRIL DR. REDDY'S LABORATORIES LTD. (IN) 2006-02-09 WO disclosed
WO-2006014916-A2 PREPARATION OF TRANDOLAPRIL DR. REDDY'S LABORATORIES LTD. (IN) 2006-02-09 WO disclosed
US-20020049155-A1 Cobalamin compounds useful as cardiovascular agents and as imaging agents HOGENKAMP HENRICUS P C (US) 2002-04-25 US disclosed
WO-2001092283-A2 COBALAMIN COMPOUNDS USEFUL AS CARDIOVASCULAR AGENTS AND AS IMAGING AGENTS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079698-A1 Process for the preparation of intermediates of trandolapril and use thereof for the preparation of trandolapril TFPI2, TFPI, TPH2 ACE 626/4885MEN1 3632/4885KMT2A 1474/4885
US-20020049155-A1 Cobalamin compounds useful as cardiovascular agents and as imaging agents APOB, MMAB, CBS ACE 2416/4885MEN1 118/4885KMT2A 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.